The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

March and will be live streamed on the Virtual Congress Platform. New results on the long-term anti-tumour activity of immunotherapy combined with chemotherapy in various non-small cell lung cancer ...

The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...

An analysis by scientists from Indian Council of Medical Research, published in The Lancet Regional Health-Southeast Asia, ...

PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell ...

A team of international scientists has developed a method to predict the risk of developing cancer from a blood disorder common in older adults, according to a study published in the journal Blood.

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

Melanoma in adolescents and young adults (AYAs) has distinct epidemiologic characteristics, with a declining incidence over the past 2 decades but an increasing trend in all-cause and cancer-specific ...